Enanta Pharma (ENTA) Misses Q2 EPS by 11c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.09), $0.11 worse than the analyst estimate of ($0.98). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $24.38 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'